Overview

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2027-01-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Centessa Pharmaceuticals (UK) Limited

Collaborator:

LockBody Therapeutics Ltd